Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4895655 | PMC |
| http://dx.doi.org/10.1111/jvim.13636 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Uncommon and Unfavorable: Heparin-Induced Hyperkalemia.
J Cardiothorac Vasc Anesth
September 2024
Department of Anesthesiology, University of Florida Health, Jacksonville, FL; Department of Anaesthesiology, Royal Brompton Hospital, London, United Kingdom.
Heparin-induced hyperkalemia, can LMWH cause hyperkalemia? A systematic review.
EJHaem
November 2023
Trauma and Orthopaeics Division Barts Health NHS Trust London UK.
Hyperkalemia, an elevated blood potassium concentration exceeding 5.0 mEq/L, is associated with adverse outcomes and is frequently observed in hospitalized patients. Drug-induced hyperkalemia accounts for a significant proportion of cases, with heparin, commonly used for venous thrombosis prevention, suspected to contribute, though less recognized than other heparin-related side effects.
View Article and Find Full Text PDFA 77-Year-Old Man with Heparin-Induced Aldosterone Suppression Causing Hyperkalemia.
Am J Case Rep
July 2022
Department of Internal Medicine, Hackensack Meridian Health, Raritan Bay Medical Center, Perth Amboy, NJ, USA.
BACKGROUND Anticoagulation with heparin infrequently causes elevated serum potassium via a reduction in the number and affinity of adrenal angiotensin II receptors, causing reversible aldosterone suppression, thereby leading to enhanced sodium excretion and hyperkalemia. CASE REPORT A 77 year-old man presented with productive cough and shortness of breath and was subsequently found to have non-ST-elevation myocardial infarction and concomitant symptomatic COVID-19 infection, for which he was started on a high-dose unfractionated heparin infusion. A gradual increase in serum potassium followed, with a subsequent return to a normal potassium level after stopping treatment with heparin.
View Article and Find Full Text PDFUse of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: A systematic review.
Artif Organs
December 2022
Department of Anaesthesia and Intensive Care, A.O.U. "Policlinico-San Marco", Catania, Italy.
Background: Extracorporeal membrane oxygenation (ECMO) represents an advanced option for supporting refractory respiratory and/or cardiac failure. Systemic anticoagulation with unfractionated heparin (UFH) is routinely used. However, patients with bleeding risk and/or heparin-related side effects may necessitate alternative strategies: among these, nafamostat mesilate (NM) has been reported.
View Article and Find Full Text PDFIneffectiveness of Intermittent Hemodialysis in a Critically Ill COVID-19 Patient: A Case of Persistent Heparin-Induced Hyperkalemia.
Case Rep Nephrol
March 2022
Intensive Care Unit, Centre Médical de Kinshasa, Kinshasa, Democratic Republic of the Congo.
Heparin is widely used in the intensive care unit despite the risk of bleeding it can cause. Although it is rarely reported, hyperkalemia is one of the side effects associated with heparin therapy (unfractionated or fractionated heparin). It would be secondary to hypoaldosteronism by blocking the biosynthesis of aldosterone in the adrenal gland and often appears in context of prolonged heparin therapy or inappropriate renin production in elderly, diabetic, and kidney insufficiency patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!